| Extension Study of Enteric-coated Mycophenolate Sodium With Short-term or no Steroid Use Compared With Enteric-coated Mycophenolate Sodium With Standard Steroid Therapy in de Novo Kidney Recipients (NCT00240955) | Novartis | 2004-03-01 |
| Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation (NCT00141037) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-03-01 |
| TAIZ -Monocytes for the Induction of Donor Specific Tolerance in Renal Allograft Recipients (Cadaver Kidney) (NCT00223093) | University Hospital Schleswig-Holstein | 2004-02-01 |
| Pharmacokinetics of Everolimus and Enteric-Coated Mycophenolatesodium Before and After Withdrawal of Cyclosporine in Renal Transplant Patients (NCT00443937) | Charite University, Berlin, Germany | 2004-01-01 |
| Safety, Tolerability and Efficacy of Everolimus With Lower Versus Higher Levels of Tacrolimus in de Novo Renal Transplant Patients (NCT00170833) | Novartis Pharmaceuticals | 2003-11-01 |
| A Study to Evaluate FK778 in Kidney Transplant Patients (NCT00189735) | Astellas Pharma Inc | 2003-09-01 |
| Influenza Vaccination in Hemodialysis Patients and Renal Transplant Recipients (NCT00776750) | Universitaire Ziekenhuizen KU Leuven | 2003-09-01 |
| A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection (NCT00089947) | Genzyme, a Sanofi Company | 2003-06-01 |
| Reducing the Risk of Transplant Rejection: Simultaneous Kidney and Bone Marrow Transplant (NCT00063817) | National Institute of Allergy and Infectious Diseases (NIAID) | 2003-06-01 |
| Fibrin Sealant in Renal Transplantation (NCT00910052) | Hennepin County Medical Center, Minneapolis | 2003-05-01 |
| Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients (NCT00239785) | Novartis Pharmaceuticals | 2003-04-01 |
| Cranoc Lipid Study in Renal Transplantation (NCT00223041) | University Hospital Schleswig-Holstein | 2003-04-01 |
| Extension Study on the Safety and Efficacy of Enteric-coated Mycophenolate Sodium in Kidney Transplant Recipients (NCT00239070) | Novartis | 2003-04-01 |
| Lowering Total Immunosuppressive Load in Renal Transplant Recipients More Than 12 Months Posttransplant (NCT00148252) | University of Oslo School of Pharmacy | 2003-02-01 |
| Extension Study of Enteric-coated Mycophenolate Sodium in Combination With Full Dose or Reduced Dose Cyclosporine Microemulsion in Patients With de Novo Kidney Transplants (NCT00238940) | Novartis | 2003-02-01 |
| Optimizing Prograf® Therapy in Renal Transplant Patients (NCT00297765) | Astellas Pharma Inc | 2003-01-01 |
| A Study to Investigate the Tolerability and Safety of Converting Stable Renal Transplant Recipients Who Receive Tacrolimus With or Without Corticosteroids From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS) (NCT00238979) | Novartis Pharmaceuticals | 2003-01-01 |
| Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation (NCT00685061) | University of Miami | 2002-11-01 |
| Extension Study to Assess Tolerability and Safety of Enteric-coated Mycophenolate Sodium in Renal Transplant Recipients Who Received Mycophenolate Mofetil (NCT00238966) | Novartis | 2002-11-01 |
| Extension Study of the Safety and Efficacy of Enteric-coated Mycophenolate Sodium in Kidney Transplant Recipients (NCT00241059) | Novartis | 2002-08-01 |
| Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients (NCT00239902) | Novartis Pharmaceuticals | 2002-05-01 |
| MMF Monotherapy and Immune Regulation in Kidney Transplant Recipients: Part 1 Steroid Withdrawal (NCT00214279) | University of Wisconsin, Madison | 2002-05-01 |
| Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant Recipients (NCT00038948) | Wyeth is now a wholly owned subsidiary of Pfizer | 2002-01-01 |
| This is a 2-year Follow-up Study to Evaluate the Long-term Effects in Patients Who Completed the Study CRAD001A2307. (NCT00531440) | Novartis Pharmaceuticals | 2001-11-01 |
| This is a Two-year Follow-up Study to Evaluate the Long-term Safety, Tolerability and Efficacy of 2 Different Doses of Everolimus (NCT00531063) | Novartis Pharmaceuticals | 2001-11-01 |
| Immunoregulatory Effects of Immunoglobulin Induction Therapy in Renal Transplant Recipients (NCT00176059) | University of Giessen | 2001-10-01 |
| Study Evaluating Rapamune in Patients After Kidney Transplantation (NCT00240214) | Wyeth is now a wholly owned subsidiary of Pfizer | 2001-04-01 |
| Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney (NCT00035555) | Bristol-Myers Squibb | 2001-03-01 |
| A Study of Mycophenolate Mofetil and Cyclosporin, Without Concomitant Corticosteroids, After a First Renal Transplant (NCT00200551) | Nantes University Hospital | 2001-01-01 |
| Prediction of NODAT After Renal Transplantation (NCT00442988) | KU Leuven | 2000-10-01 |
| A Study to Compare Early Steroid Withdrawal and Long-Term Steroid Maintenance Therapy in Kidney Transplant Patients (NCT00650468) | Astellas Pharma Inc | 1999-11-01 |
| Long-Term Pharmacokinetics of Tacrolimus in Renal Recipients (NCT00411944) | KU Leuven | 1999-08-01 |
| Tacrolimus as Secondary Intervention vs. Continuation of Cyclosporine in Renal Transplant Patients With Chronic Renal Allograft Failure (CRAF) (NCT00637143) | Astellas Pharma Inc | 1999-04-01 |
| Study Evaluating Sirolimus and Cyclosporine in Kidney Transplant Recipients (NCT00428064) | Wyeth is now a wholly owned subsidiary of Pfizer | 1998-05-01 |
| A Belatacept Compassionate Use Study for Patients With a Kidney Transplant (NCT00719225) | Bristol-Myers Squibb | |